May 8, 2019
Xcenda Releases Report on Current Medicare Part B Drug Pricing Proposals and Implications of the International Pricing Index (IPI) Model
In 2018, the Trump Administration released a proposal that would implement price controls in Medicare Part B reimbursement for physician-administered drugs based on international prices. The Part B Access for Seniors and Physicians Coalition (ASP Coalition), in addition to other key policy stakeholders, responded to Congress and the Administration with their concerns about the IPI model and the implications for patients and providers. Xcenda, in partnership with the ASP Coalition, felt it was important to explore the implications of this wide-scale, unprecedented demonstration and the risks of moving forward with it.